Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease

BACKGROUND: The PX-104 is an oral non-steroidal agonist for the farnesoid X receptor (FXR), a key regulator of bile acid (BA), glucose and lipid homeostasis. AIMS AND METHODS: This single center, proof of concept study evaluated the efficacy, safety and tolerability of PX-104 in non-diabetic NAFLD p...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Wien Klin Wochenschr
Autors principals: Traussnigg, Stefan, Halilbasic, Emina, Hofer, Harald, Munda, Petra, Stojakovic, Tatjana, Fauler, Günter, Kashofer, Karl, Krssak, Martin, Wolzt, Michael, Trauner, Michael
Format: Artigo
Idioma:Inglês
Publicat: Springer Vienna 2020
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8116226/
https://ncbi.nlm.nih.gov/pubmed/32930860
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00508-020-01735-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars